If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Maternal bonding === Of all human bonds, the maternal bond (mother–infant relationship) is one of the strongest. The maternal bond begins to develop during pregnancy; following pregnancy, the production of oxytocin during lactation increases parasympathetic activity, thus reducing anxiety and theoretically fostering bonding. It is generally understood that maternal oxytocin circulation can predispose some mammals to show caregiving behavior in response to young of their species. Breastfeeding has been reported to foster the early post-partum maternal bond, via touch, response, and mutual gazing. Extensive claims for the effect of breastfeeding were made in the 1930s by Margaret Ribble, a champion of "infant rights," but were challenged by others. The claimed effect is not universal, and bottle-feeding mothers are generally appropriately concerned with their babies. It is difficult to determine the extent of causality due to a number of confounding variables, such as the varied reasons families choose different feeding methods. Many believe that early bonding ideally increases response and sensitivity to the child's needs, bolstering the quality of the mother–baby relationship—however, many exceptions can be found of highly successful mother–baby bonds, even though early breastfeeding did not occur, such as with premature infants who may lack the necessary sucking strength to be successfully breastfed. Research following Bowlby's observations (above) created some concern about whether adoptive parents have missed some crucial period for the child's development.
OpenAI's Sam Altman said OpenAI would "do the same," though without specifying implementation details. Later OpenAI disclosed six additional instances of "concerning model behavior" identified since March 2026. In late September 2026, leaders and senior officials from 20 countries and the European Union signed a non-binding declaration calling for AI to remain under "human direction, oversight and control," for common international safety standards, and for incident reporting, and agreed to further explore establishing a global oversight institution. Notably, the United States and China did not sign the declaration.
Primary: Sodium thiopental, 5 grams, intravenous Secondary: Midazolam, 10 mg, intramuscular; sufentanil, 450 micrograms, intramuscular; and/or hydromorphone, 40 mg, intramuscular In the brief for the U.S. courts written by accessories, the State of Ohio implies that they were unable to find any physicians willing to participate in the development of protocols for executions by lethal injection, as this would be a violation of medical ethics, such as the Geneva Promise, and such physicians would be thrown out of the medical community and shunned for engaging in such deeds, even if they could not lawfully be stripped of their license. On December 8, 2009, Kenneth Biros became the first person executed using Ohio's new single-drug execution protocol. He was pronounced dead at 11:47 am EST, 10 minutes after receiving the injection. On September 10, 2010, Washington became the second state to use the single-drug Ohio protocol with the execution of Cal Coburn Brown, who was proclaimed dead within two minutes after receiving the single-drug injection of sodium thiopental. Eight states (Arizona, Georgia, Idaho, Missouri, Ohio, South Dakota, Texas, and Tennessee) have used the single-drug execution protocol. The state of Washington used this single drug method only once, as it later abandoned the death penalty. Four additional states (Arkansas, Kentucky, Louisiana, and North Carolina) announced that they would switch to a single-drug protocol but, as of June 2025, had not executed anyone since switching protocols.
For larger-scale cider production, ciders from vats produced from different varieties of apple may be blended to accord with market taste. If the cider is to be bottled, usually some extra sugar is added for sparkle. Higher quality ciders can be made using the champagne method, but this is expensive in time and money and requires special corks, bottles, and other equipment. Some home brewers use beer bottles, which work perfectly well, and are inexpensive. This allows the cider to become naturally carbonated.
Sources: en.wikipedia.org
A codon table can be used to translate a genetic code into a sequence of amino acids. The standard genetic code is traditionally represented as an RNA codon table, because when proteins are made in a cell by ribosomes, it is messenger RNA (mRNA) that directs protein synthesis. The mRNA sequence is determined by the sequence of genomic DNA. In this context, the standard genetic code is referred to as 'translation table 1' among other tables. It can also be represented in a DNA codon table. The DNA codons in such tables occur on the sense DNA strand and are arranged in a 5′-to-3′ direction. Different tables with alternate codons are used depending on the source of the genetic code, such as from a cell nucleus, mitochondrion, plastid, or hydrogenosome. There are 64 different codons in the genetic code and the below tables; most specify an amino acid. Three sequences, UAG, UGA, and UAA, known as stop codons, do not code for an amino acid but instead signal the release of the nascent polypeptide from the ribosome. In the standard code, the sequence AUG—read as methionine—can serve as a start codon and, along with sequences such as an initiation factor, initiates translation. In rare instances, start codons in the standard code may also include GUG or UUG; these codons normally represent valine and leucine, respectively, but as start codons they are translated as methionine or formylmethionine.
== NP-Mode == A concentration of hydrogen gas is used such that it is just below the minimum required for ignition. A rubidium or cesium bead, which is mounted over the nozzle, ignites the hydrogen (by acting catalytically), and forms a cold plasma. Excitation of the alkali metal results in ejection of electrons, which in turn are detected as a current flow between an anode and cathode in the chamber. As nitrogen or phosphorus analytes exit the column, they cause a reduction in the work function of the metal bead, resulting in an increase in current. Since the alkali metal bead is consumed over time, it must be replaced regularly .
Having "engaged in practices that exposed players to significant risks to their health and safety as well as the risk of using substances that were prohibited by the AFL Anti-Doping Code and the World Anti-Doping Code". Allowing "a culture of frequent, uninformed and unregulated use of the injection of supplements" at the club. Had "failed to meaningfully inform players of the substances the subject of the program and obtain their informed consent to the administration of the substances". Having an incomplete record-keeping system made it impossible to determine with certainty whether or not players had been administered banned supplements. The bypassing of human resources practices relating specifically to the employment of Robinson and Dank. The interim report found that Essendon had intended the program to be an innovative program of unprecedented scale to deliver a competitive edge to the club, but that it had not done adequate research nor established clear lines of accountability for those implementing the program. The AFL Tribunal later commented that there was a "deplorable absence of records in the program relating to its administration." Essendon and the AFL discussed and negotiated penalties for the charges over two days in August. On 27 August 2013, five days before the final round of the 2013 home-and-away season, the following penalties were agreed to and imposed:
Sources: en.wikipedia.org
complete encasement in concrete square column. wrapping the i-beam in a thin layer of metal lath and then covering it with gypsum plaster. This method is effective because gypsum plaster contains water crystals that are heat resistant. applying multiple layers of gypsum board around the i-beam. applying spray-on fireproofing around the i-beam. Also called spray-applied fire-resistive materials (SFRM) using air pressured spray gun, which can be made from gypsum plaster, mineral fibers mixed with inorganic binder or a cementitious formula using magnesium oxychloride cement. enclosing the i-beam in sheet metal and fill with loose insulation. hollow columns filled with liquid water or antifreeze. When part of the column is exposed to fire, the heat is dissipated throughout by the convection property of the liquid. encasing the i-beam in rigid concrete slab. a layer of suspended plaster ceiling isolating the i-beam
Russian novelist Eduard Limonov recounts his personal experience being put under insulin shock therapy in his 1986 novel A Young Scoundrel, scenes from which are adapted for film in the 2004 crime comedy-drama It's Russian.
The relationship between sex steroids and SHBG in physiological and pathological conditions is complex, as various factors may influence the levels of plasma SHBG, affecting bioavailability of testosterone.
=== Venezuela === Early on 3 September, tributes containing photos, videos and names of the deceased began to appear on social media. There was no response from the Maduro administration for four hours after the strike was announced; Freddy Ñáñez, the Venezuelan communications minister, was the first Venezuelan official to address the strike. He stated that the footage of the attack was fake. Inhabitants of San Juan de Unare disagree with this version. During his regular TV show on 3 September, Diosdado Cabello, Venezuela's Minister of Interior, Justice and Peace, characterized the strike as "fake news" "invented" by the US as a cover for regime change. In the TV segment, he called the killings extrajudicial murders. Cabello later said that Venezuelan investigations determined none of the 11 people killed were members of Tren de Aragua. A neighbor of one of the missing people disagreed with this version. The next day, on 4 September, Attorney General Tarek William Saab said the attack never occurred. Maduro accused the US of threatening regime change with the strike and build up of naval forces in the area. He said there were no criminal connections to drug traffickers. Delcy Rodríguez, the vice president of Venezuela, asked on 8 September, "How can there be a drug cartel if there's no drugs here?" In November 2025, Yván Gil, Venezuela's foreign minister, issued a statement saying that "Venezuela categorically, firmly, and absolutely rejects the new and ridiculous fabrication by the Secretary of the U.S.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.